Insights

Providing the latest information from our experts at Forge
January, 31 2024 in
Comprehensive Characterization of Plasmid and AAV Gene Therapy Products with Forge Biologics’ Hybrid Sequencing Approach

Comprehensive characterization of plasmid and AAV gene therapy products with Forge...

January, 16 2024 in
Forge Publication in Human Gene Therapy: A Novel Finding That Changes a Fundamental Understanding of AAV Production

A Novel Role for the Adenovirus L4 Region 22K and 33K Proteins in Adeno-Associated Virus...

December, 14 2023 in
Scaling to New Heights: Robust Scale Up to Commercial Manufacturing

Scaling to New Heights: Robust Scale Up from Shake Flask to Commercial AAV Manufacturing...

November, 14 2023 in
23 Questions With Keerthana Subramanian on Downstream Process Development

23 Questions with Keerthana Subramanian on Downstream Process Development

October, 17 2023 in
Starting With the End in Mind

Starting With the End in Mind

September, 11 2023 in
23 Questions With Claire Marasco on Global Regulatory Strategies

23 Questions with Claire Marasco on Global Regulatory Strategies

April, 3 2023 in
Forge Biologics’ cGMP Compliant and Commercially Viable Bespoke Affinity Chromatography Platform

Forge Biologics’ cGMP Compliant and Commercially Viable Bespoke Affinity Chromatography...

December, 1 2022 in
Streamline the AAV Manufacturing Process with High-Grade Starting Materials

 Streamline the AAV Manufacturing Process with High-Grade Starting Materials Authors: